First Commonwealth Financial Corp PA Decreases Stake in DexCom, Inc. (NASDAQ:DXCM)

First Commonwealth Financial Corp PA lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 14.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,800 shares of the medical device company’s stock after selling 1,500 shares during the quarter. First Commonwealth Financial Corp PA’s holdings in DexCom were worth $590,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC lifted its position in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after acquiring an additional 6,544,102 shares during the period. Legal & General Group Plc raised its position in shares of DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in DexCom by 11.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after buying an additional 288,381 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after buying an additional 353,019 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 0.1 %

Shares of NASDAQ:DXCM traded down $0.05 during midday trading on Wednesday, hitting $77.89. The company had a trading volume of 82,766 shares, compared to its average volume of 3,923,074. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a fifty day simple moving average of $70.94 and a 200 day simple moving average of $88.58. The stock has a market cap of $30.42 billion, a price-to-earnings ratio of 46.67, a PEG ratio of 2.38 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DXCM shares. Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Wells Fargo & Company increased their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Stifel Nicolaus upped their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Raymond James reduced their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.